C.2 SUNFISH Parts 1 and 2: 4-Year Efficacy and Safety Data of Risdiplam in Types 2 and 3 Spinal Muscular Atrophy (SMA)

JK Mah,M Oskoui, JW Day, N Deconinck, E Mazzone, A Nascimento, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner,A Kostera-Pruszczyk, L Servais, J Braid, M Gerber,K Gorni, C Martin, W Yeung,RS Scalco, E Mercuri

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques（2023）

引用 0|浏览1